Citation: | HOU Kai, TAN Haoyu, LIU Jing, LI Yunman. Advance of novel target strategies participating in myocardial ischemia reperfusion injury[J]. Journal of China Pharmaceutical University, 2022, 53(2): 164-170. DOI: 10.11665/j.issn.1000-5048.20220205 |
[1] |
. Exp Ther Med,2015,9(2):603-611.
|
[2] |
Hou K,Li YM. Developments on novel molecular targets participating in myocardial ischemia reperfusion injury[J]. Med Res Educ(医学研究与教育),2020,37(3):1-9.
|
[3] |
Heusch G. Myocardial ischaemia-reperfusion injury and cardioprotection in perspective[J]. Nat Rev Cardiol,2020,17(12):773-789.
|
[4] |
Hausenloy DJ,Botker HE,Engstrom T,et al. Targeting reperfusion injury in patients with ST-segment elevation myocardial infarction:trials and tribulations[J].Eur Heart J,2017,38(13):935-941.
|
[5] |
Heusch G,Gersh BJ. The pathophysiology of acute myocardial infarction and strategies of protection beyond reperfusion:a continual challenge[J].Eur Heart J,2017,38(11):774-784.
|
[6] |
Hausenloy DJ,Garcia-Dorado D,B?tker HE,et al. Novel targets and future strategies for acute cardioprotection:position paper of the european society of cardiology working group on cellular biology of the heart[J].Cardiovasc Res,2017,113(6):564-585.
|
[7] |
Inserte J,Hernando V,Vilardosa ú,et al. Activation of cGMP/protein kinase G pathway in postconditioned myocardium depends on reduced oxidative stress and preserved endothelial nitric oxide synthase coupling[J].J Am Heart Assoc,2013,2(1):
|
[8] |
Szabó MR,Pipicz M,Csont T,et al. Modulatory effect of myokines on reactive oxygen species in ischemia/reperfusion[J].Int J Mol Sci,2020,21(24):9382.
|
[9] |
Kleinbongard P,Amanakis G,Skyschally A,et al. Reflection of cardioprotection by remote ischemic perconditioning in attenuated ST-segment elevation during ongoing coronary occlusion in pigs:evidence for cardioprotection from ischemic injury[J] Circ Res,2018,122(8):1102-1108.
|
[10] |
Figueras J,Otaegui I,Marti G,et al. Area at risk and collateral circulation in a first acute myocardial infarction with occluded culprit artery. STEMI vs non-STEMI patients[J]. Int J Cardiol,2018,259:14-19.
|
[11] |
Ibanez B,James S,Agewall S,et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation:the Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC)[J].Eur Heart J,2018,39(2):119-177.
|
[12] |
Abrial M,da Silva CC,Pillot B,et al. Cardiac fibroblasts protect cardiomyocytes against lethal ischemia-reperfusion injury[J].J Mol Cell Cardiol,2014,68:56-65.
|
[13] |
Hausenloy DJ,Chilian W,Crea F,et al. The coronary circulation in acute myocardial ischaemia/reperfusion injury:a target for cardioprotection[J].Cardiovasc Res,2019,115(7):1143-1155.
|
[14] |
Schanze N,Bode C,Duerschmied D. Platelet contributions to myocardial ischemia/reperfusion injury[J].Front Immunol,2019,10:1260.
|
[15] |
Fernández-Jiménez R,Barreiro-Pérez M,Martin-García A,et al. Dynamic edematous response of the human heart to myocardial infarction:implications for assessing myocardial area at risk and salvage[J].Circulation,2017,136(14):1288-1300.
|
[16] |
Schwiebert C,Huhn R,Heinen A,et al. Postconditioning by xenon and hypothermia in the rat heart in vivo[J].Eur J Anaesthesiol,2010,27(8):734-739.
|
[17] |
Alburquerque-Béjar JJ,Barba I,Inserte J,et al. Combination therapy with remote ischaemic conditioning and insulin or exenatide enhances infarct size limitation in pigs[J].Cardiovasc Res,2015,107(2):246-254.
|
[18] |
Sun JH,Aponte AM,Menazza S,et al. Additive cardioprotection by pharmacological postconditioning with hydrogen sulfide and nitric oxide donors in mouse heart:S-sulfhydration vs. S-nitrosylation[J].Cardiovasc Res,2016,110(1):96-106.
|
[19] |
Alexopoulos P,Panoutsopoulou K,Vogiatzis G,et al. Combined treatment with exenatide and cyclosporine A or parstatin 1-26 results in enhanced reduction of infarct size in a rabbit model[J].J Cardiovasc Pharmacol,2017,70(1):34-41.
|
[20] |
Koshinuma S,Miyamae M,Kaneda K,et al. Combination of necroptosis and apoptosis inhibition enhances cardioprotection against myocardial ischemia-reperfusion injury[J].J Anesth,2014,28(2):235-241.
|
[21] |
Audia JP,Yang XM,Crockett ES,et al. Caspase-1 inhibition by VX-765 administered at reperfusion in P2Y 12 receptor antagonist-treated rats provides long-term reduction in myocardial infarct size and preservation of ventricular function[J].Basic Res Cardiol,2018,113(5):32.
|
[22] |
Aryal B,Price NL,Suarez Y,et al. ANGPTL4 in metabolic and cardiovascular disease[J]. Trends Mol Med,2019,25(8):723-734.
|
[23] |
Lux A,Pokreisz P,Swinnen M,et al. Concomitant phosphodiesterase 5 inhibition enhances myocardial protection by inhaled nitric oxide in ischemia-reperfusion injury[J].J Pharmacol Exp Ther,2016,356(2):284-292.
|
[24] |
Yang XM,Cui L,White J,et al. Mitochondrially targeted Endonuclease III has a powerful anti-infarct effect in an in vivo rat model of myocardial ischemia/reperfusion[J].Basic Res Cardiol,2015,110(2):3.
|
[25] |
Xin P,Zhu W,Li J,et al. Combined local ischemic postconditioning and remote perconditioning recapitulate cardioprotective effects of local ischemic preconditioning[J].Am J Physiol Heart Circ Physiol,2010,298(6):H1819-H1831.
|
[26] |
Huang MH,Wu YW,Nguyen V,et al. Heart protection by combination therapy with esmolol and milrinone at late-ischemia and early reperfusion[J].Cardiovasc Drugs Ther,2011,25(3):223-232.
|
[27] |
Fan Y,Yang SS,Zhang XK,et al. Comparison of cardioprotective efficacy resulting from a combination of atorvastatin and ischaemic post-conditioning in diabetic and non-diabetic rats[J]. Clin Exp Pharmacol Physiol,2012,39(11):938-943.
|
[28] |
Tratsiakovich Y,Gonon AT,Kiss A,et al. Myocardial protection by co-administration of L-arginine and tetrahydrobiopterin during ischemia and reperfusion[J].Int J Cardiol,2013,169(1):83-88.
|
[29] |
Wang Q,Liu GP,Xue FS,et al. Combined vagal stimulation and limb remote ischemic perconditioning enhances cardioprotection via an anti-inflammatory pathway[J].Inflammation,2015,38(5):1748-1760.
|
[30] |
Eitel I,Stiermaier T,Rommel KP,et al. Cardioprotection by combined intrahospital remote ischaemic perconditioning and postconditioning in ST-elevation myocardial infarction:the randomized LIPSIA CONDITIONING trial[J].Eur Heart J,2015,36(44):3049-3057.
|
[31] |
Pasupathy S,Tavella R,Grover S,et al. Early use of N-acetylcysteine with nitrate therapy in patients undergoing primary percutaneous coronary intervention for ST-segment-elevation myocardial infarction reduces myocardial infarct size (the NACIAM trial[N-acetylcysteine in acute myocardial infarction])[J].Circulation,2017,136(10):894-903.
|
[32] |
Rout A,Sukhi A,Chaudhary R,et al. Investigational drugs in phase II clinical trials for acute coronary syndromes[J].Expert Opin Investig Drugs,2020,29(1):33-47.
|
[33] |
Ziegler M,Haigh K,Nguyen T,et al. The pulmonary microvasculature entraps induced vascular progenitor cells (iVPCs) systemically delivered after cardiac ischemia-reperfusion injury:indication for preservation of heart function via paracrine effects beyond engraftment[J]. Microcirculation,2019,26(2):
|
[34] |
Audia JP,Yang XM,Crockett ES,et al. Caspase-1 inhibition by VX-765 administered at reperfusion in P2Y 12 receptor antagonist-treated rats provides long-term reduction in myocardial infarct size and preservation of ventricular function[J].Basic Res Cardiol,2018,113(5):32.
|
[35] |
Rossello X,Yellon DM. The RISK pathway and beyond[J]. Basic Res Cardiol,2017,113(1):1-5.
|
[36] |
Yang XL,Yue RC,Zhang J,et al. Gastrin protects against myocardial ischemia/reperfusion injury via activation of RISK (reperfusion injury salvage kinase) and SAFE (survivor activating factor enhancement) pathways[J].J Am Heart Assoc,2018,7(14):
|
[37] |
Olshan DS,Rader DJ. Angiopoietin-like protein 4:a therapeutic target for triglycerides and coronary disease[J]?J Clin Lipidol,2018,12(3):583-587.
|
[38] |
Gibson CM,Giugliano RP,Kloner RA,et al. EMBRACE STEMI study:a Phase 2a trial to evaluate the safety,tolerability,and efficacy of intravenous MTP-131 on reperfusion injury in patients undergoing primary percutaneous coronary intervention[J].Eur Heart J,2016,37(16):1296-1303.
|
1. |
熊坚,黄小刚,赵惠芳,凌发样,郑倩华,王姿雯,齐文川,梁繁荣. 针灸治疗心肌缺血再灌注损伤研究现状与热点分析. 世界科学技术-中医药现代化. 2025(01): 179-194 .
![]() | |
2. |
门汝梅,王艳林,张琳娜,门丽丽,兰文达,孟庆兰,于建才. 美托洛尔联合氯吡格雷对心肌缺血再灌注损伤小鼠的作用机制. 西部医学. 2024(03): 365-371 .
![]() | |
3. |
山文菊,崔君,蹇玉红,封林奇,易蔚,孙阳. 衣康酸在心肌缺血再灌注损伤中的动态变化及其作用研究. 中国体外循环杂志. 2024(02): 139-144 .
![]() | |
4. |
贾凌梅,陈亚丽,贾敏,刘畅,栾莹莹,张颖. 参松养心胶囊通过铁死亡途径保护心肌缺血再灌注损伤研究. 现代中西医结合杂志. 2024(08): 1072-1076 .
![]() | |
5. |
李萍,洪薇,雷晓燕,闫莉. 急诊护理分级责任制整体服务对急性心肌梗死患者的抢救效果. 名医. 2024(04): 132-134 .
![]() | |
6. |
魏琴,陈冰心,赵翎,阿曼古丽·如则,赵帮豪,姜涛,张春,李志强,段明军,高晓明. 松弛素抑制氧化应激反应保护小鼠心肌微血管内皮细胞的缺氧/复氧损伤. 中国组织工程研究. 2023(23): 3621-3627 .
![]() | |
7. |
郑祥,王审. 自拟活血舒痹汤治疗急性心肌梗死PCI术后缺血再灌注损伤的临床研究. 中华全科医学. 2023(06): 966-969+972 .
![]() | |
8. |
毛雨,沈童童,费亮,王健,陈良余. CHA2DS2-VASc评分、血清肌酐对急性ST段抬高型心肌梗死介入术后发生院内不良事件的预测价值. 山东医药. 2023(22): 61-64 .
![]() | |
9. |
吴丛宇,周悦,上官璐茜,杨雅妮,王晶雅,余俊河,宫帅帅,寇俊萍. 大黄素的药理作用机制研究进展. 中国药科大学学报. 2023(05): 634-643 .
![]() | |
10. |
刘盼,王晓英,韩丹. 地黄苷A通过调节AKT/Nrf2/GPX4信号通路介导的铁死亡改善大鼠心肌缺血再灌注损伤. 中西医结合心脑血管病杂志. 2023(22): 4112-4119 .
![]() | |
11. |
王德勇,涂英兵,袁娟,张珏,张禾. 基于PERK/Nrf2/HO-1信号通路研究瑞马唑仑对心肌缺血再灌注损伤大鼠铁死亡的影响. 现代生物医学进展. 2023(23): 4427-4433 .
![]() | |
12. |
骆春旭. 迷迭香酸在心血管疾病中的应用研究进展. 生物化工. 2022(04): 151-153+158 .
![]() |